Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 24, 2015 5:34 PM ET

Life Sciences Tools and Services

Company Overview of Drug Safety Alliance, Inc.

Company Overview

Drug Safety Alliance, Inc. provides safety and risk management services to support pharmaceutical, biotech, medical device, consumer health, and animal health organizations. The company focuses on pharmacovigilance; and provides outsourced solutions and modified services to augment existing safety departments. It offers full-service pharmacovigilance solutions, such as comprehensive case management, global aggregate report development, literature search, risk management, pharmacovigilance system master file, QPPV support, medical writing, and audit inspection readiness services, as well as signal surveillance activities; and tailored pharmacovigilance solutions, such as legal/litigation case...

5003 South Miami Boulevard

Suite 500

Durham, NC 27703

United States

Founded in 2000





Key Executives for Drug Safety Alliance, Inc.

Chief Executive Officer
Chief Operating Officer
Senior Director of Operations
Director of Regulatory Affairs
Compensation as of Fiscal Year 2015.

Drug Safety Alliance, Inc. Key Developments

FDA Approves Drug Safety Alliance, Inc.'s Second Vaccine to Prevent Serogroup B Meningococcal Disease

Drug Safety Alliance, Inc. announced that The U.S. Food and Drug Administration approved Bexsero, a vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.

Drug Safety Alliance, Inc Receives Approval from U.S. Food and Drug Administration to Dalvance to Treat Skin Infections

Drug Safety Alliance, Inc. announced that the U.S. Food and Drug Administration approved Dalvance (dalbavancin), a new antibacterial drug used to treat adults with skin infections.

Similar Private Companies By Industry

Company Name Region
PAREXEL Consulting Inc. United States
Greenleaf Health, LLC United States
Biolucidation, LLC United States
BioSeek Inc. United States
NuvoGen Research, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Drug Safety Alliance, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at